Generally, NGS testing already allows identifying patients with EGFR mutations for whom a specific adjuvant TKI has been approved, but also provides a broad range of targets and predictive markers, giving the potential for exploring existing and new TKIs and CPIs in early-stage NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.